Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial
Primary result · Percentage change in LDL-CResult — go to the resultBetween-group difference −41.0 % 95% CI −45.7 to −36.2Authors' conclusion
Inclisiran provided superior LDL-C reduction versus BPA with favourable safety
Study context
- Population
- Atherosclerotic cardiovascular disease (ASCVD) patients with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL on statins (± ezetimibe)randomized
- Participants
- 402 patients
- Comparison
- Inclisiran vs bempedoic acid
- Primary endpoint
- Percentage change in LDL-C
- Follow-up
- Day 150
Methodological detailsphase 4, open-label
- Phase 4
- Open-label
Primary result
Percentage change in LDL-C
Between-group difference
−41.0 %
95% CI −45.7 to −36.2
P < 0.0001
Change by group
Inclisiran
−56.3
least squares mean · %
Bempedoic acid (BPA)
−15.4
least squares mean · %
Inclisiran vs BPA
between-group difference −41.0 % (95% CI −45.7 to −36.2); P < 0.0001
As reported in the abstract
Secondary outcomes
| Outcome | Inclisiran | BPA | Adjusted OR (95% CI) | P value | |
|---|---|---|---|---|---|
| LDL-C goal attainment · descriptive p | 78.2% | 20.3% | 16.36 (9.72–27.54) | P < 0.0001 | |
| 0.050.21520Adjusted odds ratio (log scale) |
mg/dL
| Outcome | Inclisiran | BPA | Estimate | P value |
|---|---|---|---|---|
| Absolute LDL-C change · Day 150 | −53.4 | −17.5 |
Absolute LDL-C change · Day 150
- Greater reduction with inclisiran regardless of ezetimibe use
Safety
TEAEs
Serious TEAEs
Nasopharyngitis
Hypertension
Myalgia
- Treatment-emergent adverse events (TEAEs) — Non-treatment-related death (inclisiran)
- 1
Original publication
Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial. Eur Heart J. Published 31 August 2026. doi:10.
Summarised from the published abstract; every number is checked against it